Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 23, 2021 08:00 ET
|
Rubius Therapeutics
Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in...
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
February 09, 2021 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood...
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
February 03, 2021 16:45 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
January 11, 2021 08:00 ET
|
Rubius Therapeutics
Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021 IND Cleared and...
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 16:01 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
November 30, 2020 16:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
November 10, 2020 16:01 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
November 09, 2020 08:05 ET
|
Rubius Therapeutics
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Filed...
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
November 09, 2020 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...